GLP-1 Pill Orforglipron More Effective Than Rybelsus in Late-Stage Diabetes Trial

Everyday Health·Feb 27

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A late-stage trial has found that the glp-1 pill orforglipron is more effective than rybelsus in treating diabetes. The pill, developed by lilly, has also shown promise in weight loss and blood sugar control. Reports suggest that the pill may be approved by the fda, potentially leading to competition with novo nordisk in the glp-1 market.

Full coverage

Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

BioPharma Dive·Feb 26

New Oral Drug Foundayo for Weight Loss

Making Sense of Diabetes·Apr 20

2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market

CNBC·Jan 10

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound

CNBC·Dec 18

View original report at Everyday Health ↗

Fetching the latest headlines…

GLP-1 Pill Orforglipron More Effective Than Rybelsus in Late-Stage Diabetes Trial

Full coverage

Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

New Oral Drug Foundayo for Weight Loss

2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market

Lilly's weight-loss pill shows better blood sugar control in late-stage trials

Lilly's GLP-1 diabetes pill beats Novo's Rybelsus in a head-to-head trial

Orforglipron Pill: What We Know So Far About The New Weight Loss Pill

FDA approves Lilly obesity pill, triggering battle with Novo Nordisk

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound